© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Rosiglitazone stands as a product of late-twentieth-century efforts to address rising type 2 diabetes rates. Back in the 1980s, researchers recognized that insulin resistance, not just insulin deficiency, played a bigger role in diabetes than once thought. Scientists in the United Kingdom and Japan developed a new class called thiazolidinediones, and rosiglitazone arrived as a promising candidate by the mid-90s. At the start, there was intense optimism. Drugs like rosiglitazone provided an option beyond old-school sulfonylureas or metformin, with animal and early clinical results showing improved blood sugar management by targeting peroxisome proliferator-activated receptor gamma (PPAR-γ). GlaxoSmithKline ran large-scale trials and, by 1999, rosiglitazone gained FDA approval. The glow didn’t last forever. After years on the market, cardiovascular risk concerns led to ongoing debate about its risk-benefit balance, prompting label changes, prescribing restrictions, and ongoing scrutiny by regulators and researchers.
Rosiglitazone base, a thiazolidinedione derivative, enters tablets or bulk powders for use in pharmaceutical manufacturing. The pure base is not the prescribed form for patients; commercial tablets usually use rosiglitazone maleate to help with stability and handling. In its base form, it offers a molecule that links directly back to the PPAR-γ target. Interest in its base version often arises from industrial R&D, generic production, analytical labs, or academic chemistry settings. Researchers spend real time working out the best pathways to build the molecule, purify it, and check for impurities that impact final clinical safety.
Rosiglitazone base appears as a pale, white, or slightly yellow crystalline powder. It melts at about 122-123°C. Its chemical name, 5-[(2-(methyl-2-pyridinylamino)ethoxy)benzyl]thiazolidine-2,4-dione, hints at its biphilic structure—thiazolidinedione rings, ether chains, and pyridine groups. It dissolves poorly in water, better in ethanol or dimethyl sulfoxide, making API processing and formulation challenging. Lab teams often adjust pH, switch solvents, or tweak order of addition to boost recovery.
Pharmaceutical wholesalers and manufacturers care about purity, water content, residual solvents, heavy metal content, and polymorphism. Rosiglitazone’s certificate of analysis keeps strict targets: over 99% purity by HPLC, low single-digit ppm for heavy metals, and minimal organic volatile impurities. Labels must follow current Good Manufacturing Practice (cGMP) protocols, indicating storage temperature—away from light, cool and dry, usually under 25°C—and clear batch, manufacturing, and expiry dates. Because its oral use affects metabolic function, traceability and documentation remain central for every lot.
Chemists synthesize rosiglitazone starting from basic thiazolidinedione intermediates. One pathway combines 2,4-thiazolidinedione with bromoalkyl aromatics under sodium carbonate or potassium carbonate catalysis, driving ether bond formation through nucleophilic substitution. Further steps attach the pyridine side chain and introduce the methylamino group. The process requires patience and cleanroom-level separation of by-products, with column chromatography or crystallization providing purity lifts. Each tweak in solvent, reaction temperature, or catalyst changes the impurity profile and total yield, forcing chemistry teams to fine-tune every stage for scale-up.
Rosiglitazone’s structure opens doors for both minor tweaks and major overhaul by medicinal chemists. Swapping in different aryl or heterocyclic groups at the ether, thiazolidinedione, or aminopyridine sections changes how tightly and selectively it binds to PPAR-γ. Over the years, chemists aimed to boost potency or cut out the cardiovascular side effects. Some tried adding bulky groups to block metabolism, others used prodrug strategies to deliver the drug only in target organs. Analytical teams often rely on NMR, mass spectrometry, and chiral HPLC to distinguish between active and inactive forms and chase down toxicological impurities.
Rosiglitazone base also turns up in the literature as CAS 122320-73-4, BRL-49653, Avandia (as the maleate salt), and a set of longer IUPAC descriptors. Generics from Asia or Europe sometimes list it as rosiglitazonum. Chemists ordering for synthesis or assay reference need to make sure they’re getting the “base” and not the salt; otherwise, dosages and experiments give skewed results. This confusion still pops up years after patents expired, especially in translation between regulatory frameworks around the world.
Safety teams working with rosiglitazone enforce GMP rules, observe chemical hygiene, and watch for inhalation or skin exposure in powder rooms. Material Safety Data Sheets warn of possible eye, skin, or respiratory irritation. Lab techs use gloves, masks, and ventilated hood systems. Any facility dealing with large-scale synthesis double-checks for dust ignition, environmental emission, and safe waste solvent handling. Occupational hazards fade under good protocols, but at-home misuse or internet-purchased forms of APIs create new risk fronts, especially in regions with loose pharmaceutical regulation.
Treatment of type 2 diabetes remains the biggest driver. Doctors prescribe rosiglitazone for patients who have not responded well to other oral treatments, often paired with metformin or sulfonylureas. The PPAR-γ mechanism aims to ease blood glucose levels by increasing adipocyte sensitivity to insulin. Some off-label investigations have looked at inflammation, fatty liver disease, or polycystic ovary syndrome, banking on its effects in fat tissue and metabolism. Clinical teams watch for fluid retention, heart failure signals, and liver enzyme changes, reflecting lessons learned over two decades of patient use.
Development teams keep looking for safer thiazolidinediones, studying ways to minimize side effects. One route uses partial agonists or compounds that tweak PPAR-γ activity, flirting with selectivity to keep metabolic benefit but limit cardiovascular harm. Academic teams use rosiglitazone as a molecular probe, mapping downstream gene changes, secondary messengers, and cross-talk with other nuclear receptors. Drug delivery specialists also explore nanoformulations and slow-release matrices, trying to steer the drug to target tissues and cut required doses. Every so often, trial data triggers renewed interest, especially as diabetes epidemics balloon outside the developed world.
Toxicity studies picked up changes in heart, liver, and bone biology caused by rosiglitazone. Elevated risk of myocardial infarction dominated safety debate in the 2000s, splitting the medical community and sparking dozens of meta-analyses. Preclinical models showed liver fat buildup, increased adiposity, and fluid shifts, while post-marketing surveillance discovered rare but serious instances of congestive heart failure and macular edema in humans. Researchers checked for genotoxicity, reproductive toxicity, and off-target effects on fetal animal models. Regulatory scrutiny resulted in black-box warnings, registry programs, and stricter exclusion criteria in ongoing trials.
Rosiglitazone’s story reflects broader efforts in diabetes treatment—balancing tight glycemic control with long-term safety. Many patients now get alternatives with stronger cardiovascular profiles, such as SGLT2 inhibitors or GLP-1 analogs, but the hunt continues to tweak the thiazolidinedione core or find better receptor modulators. Scientists study ways to personalize therapy by linking genetics, gut microbiome changes, and metabolic state. In emerging markets, lower-cost generics still provide a lifeline for many living with diabetes. Regulatory and clinical scientists keep digging for biomarkers that predict which patients will benefit or suffer harm, hoping for another chapter where PPAR-γ targeting drugs can safely fit in modern care.
Rosiglitazone base has played a role in the treatment of type 2 diabetes for a couple of decades. As a medication from the thiazolidinedione family, it works by making cells more sensitive to insulin and helps lower blood sugar. Doctors have often prescribed it for adults whose glucose levels run high even after making lifestyle changes like diet and exercise.
People living with type 2 diabetes often struggle to keep their blood sugar under control, risking complications like nerve damage, kidney problems, and even heart disease. Rosiglitazone entered the scene as a new option paired with older drugs like metformin or sulfonylureas. Its promise came from its ability to target insulin resistance, which is a root cause for many adults diagnosed with type 2 diabetes.
Before doctors had rosiglitazone in their toolbox, patients sometimes cycled through less effective medications, battling frustration along the way. Rosiglitazone gave them a fresh start. Studies showed that it not only helped control glucose but also lowered A1C levels for many people. For families worried about long-term complications, this medicine brought hope.
But drugs rarely come without drawbacks. Over time, regulators took a closer look at rosiglitazone. Researchers found that it could raise the risk of cardiovascular issues in some people. By 2010, warnings appeared and its use dropped sharply in many countries. Safety keeps evolving with rare side effects like fluid retention or bone fractures coming to light. None of this erased its original value for patients whose bodies simply did not react to other drugs.
Doctors learned to pick patients carefully. Someone with a prior heart issue, liver problem, or risk factor might look for another option. For healthier adults without those issues, rosiglitazone could still do what it set out to do: help lower blood sugar by improving how the body handles insulin.
I remember family friends struggling to get a handle on daily glucose checks, changing diets, and juggling multiple prescriptions. The appeal of a new drug—one promising more consistent blood sugar—stood out to them. Seeing some achieve better numbers in their bloodwork, along with fewer symptoms, makes it clear why rosiglitazone earned a following, at least at the start.
Rosiglitazone sits among a group of diabetes medications where doctors now weigh risks and benefits much more carefully. Strong reporting systems, better screening, and open doctor-patient conversations about side effects are critical. Modern care draws on lessons from rosiglitazone’s history. Patients today get more than just a script—they get education, support, and options tailored to real needs.
Science pushes doctors to rethink older medicines regularly. Rosiglitazone started with promise, faced real challenges, and continues to influence how society looks at safety in chronic disease management. For anyone with type 2 diabetes, it makes sense to talk to healthcare providers, stay informed, and remember that there’s no “one-size-fits-all” answer—personal experience and careful monitoring matter more than ever.
Rosiglitazone Base falls into the thiazolidinedione family, often prescribed for people with type 2 diabetes. It works by helping the body use insulin more effectively. The goal is better blood sugar control, which can mean smoother days for many living with diabetes. Still, any pill that nudges the body's hormones and metabolism tends to set off some side effects—sometimes mild, other times more worrying.
Nausea, stomach pain, and swelling can pop up in the first weeks after starting rosiglitazone. Some folks get an upset stomach or notice a heavier feeling in their abdomen. Diarrhea and flatulence don’t always get mentioned in glossy brochures, but real-world experience proves these side effects matter to those trying to build healthy habits. These symptoms can even steer some people towards skipping doses or quitting the medication altogether. If these problems don’t fade after a couple of weeks, a chat with your doctor can help clear things up or lead to other treatment options.
Weight gain stands out among the reasons some patients hesitate to stay on rosiglitazone. Sometimes that weight comes from fluid, not just fat. The body's tissues start holding onto water, leading to puffy ankles, swelling in the hands, and even bloating in the belly. People with heart issues need to pay close attention here. Extra fluid can make underlying conditions worse. The U.S. Food and Drug Administration (FDA) put a warning label on rosiglitazone for this very reason. In diabetes clinics, doctors often see folks who didn’t catch the early warning signs, just realizing fluid buildup had been creeping in for weeks.
Reports have tied rosiglitazone to a raised risk of heart failure. That means if your heart already struggles to pump well, or if you have a prior heart issue, this drug may push problems further. A large meta-analysis in the New England Journal of Medicine flagged higher odds of heart-related events like chest pain and shortness of breath in those using rosiglitazone. That’s not just numbers on a chart—those stories belong to real people with families and plans. Health workers keep an eye out for unexplained coughing, swelling in the legs, or trouble breathing. These signals suggest the body can't handle the extra fluid load, and it's time to rethink therapy.
Years of research have shown a link between rosiglitazone and higher rates of bone fractures, especially in postmenopausal women. Osteoporosis sneaks up on people, and breaking a bone from a simple fall brings long recoveries and life changes. This risk doesn’t always show up right away; sometimes it takes months or longer on the medication. Simple advice from diabetes educators—higher calcium, walking outside, even basic strength training—can help protect bones, but the trade-off still weighs on many minds.
Doctors see better results when people discuss any new symptoms early, track their weight at home, and report sudden changes fast. Blood tests for liver function can flag early trouble, too. A tailored treatment plan, possibly including other diabetes medications, gives more people a chance to avoid side effects and still hit their blood sugar targets. Choices exist—no one needs to “just live with it.” Patient stories and strong support from care teams make all the difference.
If you know anyone living with type 2 diabetes, you might have heard stories about how challenging it gets to control blood sugar. Doctors sometimes prescribe Rosiglitazone Base to help. I’ve spent years watching friends deal with prescriptions like this, and one lesson stands out—following instructions counts for more than people think. Skipping pills, changing doses, or doubling up because of a missed dose can cause more headaches than the diabetes itself. Taking Rosiglitazone Base at the same time every day, with or without food, helps keep the medicine working steadily. Consistency isn’t about habit for habit’s sake, but about giving your body the support it expects.
Medical research shows that Rosiglitazone Base can cause fluid retention or increase the risk of heart failure in certain people. The U.S. Food and Drug Administration has placed restrictions on how it gets prescribed. This isn’t scaremongering—friends of mine on the medicine who play fast and loose with the doctor’s orders have found themselves bloated and short of breath. One trip to the emergency room is enough to show how important it is to stick with the agreed dose.
Diabetes often goes hand-in-hand with other medications. Patients juggling drugs for blood pressure, cholesterol, or heart conditions need to keep a close dialogue with their doctor. Real people—maybe your neighbor, maybe your uncle—have wound up in trouble because their meds didn’t play well together. Don’t be afraid to ask the pharmacist or doctor about interactions. These conversations can head off big problems later.
Blood tests aren’t just box-ticking. They actually tell the story of how a body’s coping with Rosiglitazone Base. Doctors use them to check for changes in liver function or blood sugar numbers. My neighbor skipped his regular appointments and started feeling sluggish and out of sorts. Lab results later showed rising liver enzymes. If he’d gone in a month earlier, he might have caught things before they snowballed.
Relying on memory alone gets tougher as life gets busier. Pill organizers, phone reminders, or even family members who serve as accountability partners can bridge that gap. Pharmacies sometimes offer blister packs, putting each day’s pills in a single bubble, making mistakes less likely. Bringing a list of all your medicines (not just Rosiglitazone Base) to appointments lets providers double-check for risky combinations. Keeping a small notebook or digital log highlighting any symptoms that crop up helps, too. If something feels off, bringing that record to the doctor paints a clearer picture.
The science gives us the basics, but it’s the way people live it out that shapes real outcomes. Taking Rosiglitazone Base as prescribed isn’t extra credit. It’s how patients get the best chance at balancing blood sugar and living life on their own terms. Trusting the advice of your prescriber, watching for any changes, and not being shy about voicing concerns can change the course of a chronic illness. That’s something I’ve witnessed in more than a few success stories—and everyone deserves a shot at the same.
Rosiglitazone helps lower blood sugar for adults living with type 2 diabetes. At one point, it felt like doctors handed it out left and right. Over time, stories came out about folks getting into trouble because of heart and liver risks. I remember meeting a patient, early in my time volunteering at a community clinic, who was thrilled her numbers dropped but had no idea what else the medicine could do. Her heart doctor later switched her to something safer.
People who already have heart failure—especially moderate or severe—should steer clear. It’s not just caution, it’s a direct line in the treatment guide. The risk of the heart not pumping enough blood goes up, sometimes fast. Fluid retention sneaks in, ankles puff up, shortness of breath sets in, and the next stop can be a hospital bed. Kidney disease raises stakes even more due to less effective fluid management. Women with osteoporosis also face more fractures using this drug.
The liver plays gatekeeper for rosiglitazone. Elevated liver enzymes or any kind of active liver disease sends up a red flag. Health Canada and FDA both issued strong advice: always do a liver panel before starting, watch for jaundice or unusual fatigue, and don’t use it if the liver struggles.
A few years ago, pharmacists flagged a big problem—patients often mixed rosiglitazone with other medicines that could make side effects worse. Gemfibrozil, for example, increases rosiglitazone levels in the body; this ramps up the risk of fluid build-up and heart problems. Rifampin works in the opposite direction, making rosiglitazone much less effective. Watching patients juggle drugs like glimepiride, insulin, or metformin brought extra concern about low blood sugar episodes. Sometimes, blood sugar would crash unexpectedly, leading to shaky hands, sweats, and ER visits.
Oral contraceptives bring their own wrinkles. Rosiglitazone can reduce hormone levels in birth control pills. Unplanned pregnancies became a real risk for women depending on the pill alone.
Having worked in primary care in neighborhoods where patients see different doctors for different needs, I often saw a simple truth—medicines prescribed by one doctor clash with those from another. It’s not laziness, just a symptom of a busy system. Care tends to improve when nurses and pharmacists check medicine lists together. Community pharmacies investing in electronic systems that quickly flag dangerous combos could prevent tragedies. I’ve seen hopeful changes where clinics do “brown bag” reviews, letting patients bring in every pill bottle for a pharmacist to review. These conversations catch mix-ups before things get out of hand.
Education makes all the difference. Patients who learn the risks—even if they feel fine in the moment—think twice before mixing a new prescription or ignoring swelling. Healthcare teams need to push hard on this step for folks getting rosiglitazone. Building trust so people actually report side effects and don’t suffer in silence goes a long way.
Most people do better with medications that have fewer landmines. Rosiglitazone can help some, but it demands careful eyes and honest conversations about real risks. Supporting patients with safer choices, strong follow-up, and teamwork paints a better future.
Doctors often prescribe Rosiglitazone Base for type 2 diabetes. It helps steady blood sugar by making body cells more sensitive to insulin. Strong as it sounds, medicine like this always carries some risk. What people do daily can shape how well it works—and how safe it stays.
The biggest worry with Rosiglitazone Base involves the heart. The FDA once placed major restrictions on this drug because many patients reported heart failure or even heart attacks. People with a history of heart disease or fluid buildup in the body have to pay even closer attention. Before starting Rosiglitazone, a visit to a heart specialist can make all the difference. Stopping the drug at the first sign of chest pain, shortness of breath, or swollen legs could prevent bigger problems.
Combining Rosiglitazone Base with other diabetes drugs, especially insulin or sulfonylureas, sometimes drops blood sugar too low. Feeling shaky, confused, or lightheaded signals the need for a snack, and perhaps a blood sugar test. Keeping emergency glucose tablets nearby helps prevent a full-blown crisis. Doctor visits offer a chance to talk about adjusting doses and watching for patterns in blood sugar spikes or dips.
The body processes Rosiglitazone Base through the liver. People with liver trouble or a history of hepatitis have to stay on guard. Blood tests before and during treatment keep doctors informed about liver health. Nausea, yellowing eyes, or dark urine could point to something serious. Open conversations with healthcare providers set the stage for quick action if warning signs show up.
Rosiglitazone Base often causes weight gain by making the body hold on to fluid. Swelling in the ankles or hands, trouble breathing, or sudden weight changes don’t belong in daily life. Regular weighing and checking for puffiness keep surprises away. This drug can also thin bones and raise the chance of fractures, especially in older women. Doctors may recommend bone scans or suggest vitamin D and calcium for added strength.
Taking Rosiglitazone at the same time every day, paired with meals, reduces stomach upset and keeps blood levels steady. Alcohol can stress the liver and cause blood sugar swings, so limiting drinks makes sense. Letting every doctor and pharmacist know about Rosiglitazone reduces the risk of drug interactions. Simple habits, like reviewing medication lists or asking questions at appointments, put control back into patients’ hands.
Safety improves when family and friends know how Rosiglitazone affects mood, body, and energy. With open conversations, the risk of missing warning signs drops. Doctors, nurses, and pharmacists all play a part in teaching, checking blood tests, and answering questions. Sometimes changes in diet or adding exercise may work better than increasing doses.
Doctors should lay out the risks clearly, right from the start. Patients need honest updates about any new symptoms. Over time, reviewing blood tests and setting up regular check-ins keep things on track. Until better options appear, using Rosiglitazone safely relies on steady routines, trust in healthcare providers, and paying attention to small changes before they turn into big ones.
| Names | |
| Preferred IUPAC name | 5-[[4-[2-(methylpyridin-2-ylamino)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione |
| Other names |
Avandia BRL 49653 Rosiglitazone Maleate BRL-49653 |
| Pronunciation | /ˌroʊ.zɪˌɡlɪ.təˈzoʊn beɪs/ |
| Identifiers | |
| CAS Number | “122320-73-4” |
| Beilstein Reference | 1412223 |
| ChEBI | CHEBI:50122 |
| ChEMBL | CHEMBL779 |
| ChemSpider | 21632018 |
| DrugBank | DB00412 |
| ECHA InfoCard | 03a9e069-5003-4b30-bb99-4826fdd8768f |
| EC Number | EC 1.14.13.39 |
| Gmelin Reference | 1422307 |
| KEGG | D08445 |
| MeSH | D056405 |
| PubChem CID | 77999 |
| RTECS number | YQ8N8291QW |
| UNII | 8P0F3O35WX |
| UN number | UN number not regulated |
| CompTox Dashboard (EPA) | DTXSID7020288 |
| Properties | |
| Chemical formula | C18H19N3O3S |
| Molar mass | 357.430 g/mol |
| Appearance | White crystalline powder |
| Odor | Odorless |
| Density | 1.256 g/cm3 |
| Solubility in water | Insoluble in water |
| log P | 2.6 |
| Vapor pressure | 3.6E-8 mm Hg at 25°C |
| Acidity (pKa) | 6.8 |
| Basicity (pKb) | 6.61 |
| Magnetic susceptibility (χ) | -12.2e-6 cm³/mol |
| Refractive index (nD) | 1.509 |
| Viscosity | Viscous liquid |
| Dipole moment | 3.9442 Debye |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 461.10 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -482.8 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -7358 kJ/mol |
| Pharmacology | |
| ATC code | A10BG02 |
| Hazards | |
| GHS labelling | GHS labelling of Rosiglitazone Base: `"Warning; H302, H315, H319"` |
| Pictograms | GHS07,GHS08 |
| Signal word | Warning |
| Hazard statements | H302 + H312 + H332: Harmful if swallowed, in contact with skin or if inhaled. |
| Precautionary statements | P264, P280, P302+P352, P305+P351+P338, P310 |
| NFPA 704 (fire diamond) | 1-1-0-ʏ |
| Flash point | 141.8°C |
| Autoignition temperature | 180 °C |
| Lethal dose or concentration | LD₅₀ (oral, rat): > 3000 mg/kg |
| LD50 (median dose) | LD50 (median dose) of Rosiglitazone Base: "365 mg/kg (rat, oral) |
| NIOSH | Not Established |
| PEL (Permissible) | PEL: Not established |
| REL (Recommended) | 2~8°C |
| IDLH (Immediate danger) | Unknown |
| Related compounds | |
| Related compounds |
Rosiglitazone Rosiglitazone Maleate Pioglitazone Troglitazone Ciglitazone |
